医学
磺胺吡啶
强的松
甲氨蝶呤
克罗恩病
疾病
甲硝唑
克罗恩病
外科
重症监护医学
内科学
溃疡性结肠炎
抗生素
微生物学
生物
出处
期刊:JAMA
[American Medical Association]
日期:1997-04-16
卷期号:277 (15): 1232-1232
被引量:290
标识
DOI:10.1001/jama.1997.03540390062037
摘要
CLINICAL SCENARIO
You are a physician following a 35-year-old man who has had active Crohn disease for 8 years. The symptoms were severe enough to require resectional surgery 4 years ago, and despite treatment with sulfasalazine and metronidazole, the patient has had active disease requiring oral steroids for the last 2 years. Repeated attempts to decrease the prednisone have failed, and the patient has required doses of greater than 15 mg per day to control symptoms. You are impressed by both the methods and results of a recent article1documenting that such patients benefit from oral methotrexate and suggest to the patient that he consider this medication. When you explain some of the risks of methotrexate, particularly potential liver toxicity, the patient is hesitant. How much better, he asks, am I likely to feel while taking this medication? INTRODUCTION
There are 3 reasons we offer treatment to our patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI